Stem cell biotech company Bioheart ($BHRT) has had a rough 2015 so far. Could this year be a decisive, negative tipping point for the company? It has a number of clinical trials going, but from my view things seem increasingly uncertain. An oddity amongst stem cell biotechs, Bioheart and its leadership have at times seemed to toy […]
Bioheart on the edge in 2015? Read More »
I invited the Chief Scientific Officer (CSO) of Bioheart, Kristin Comella, to do an interview after hearing some buzz that this could be a critical time for the company and that it might have been recently visited by the FDA. Note that Comella not just Bioheart CSO, but also the primary instructor for physician training in stem
Interview with Bioheart CSO, Kristin Comella including on FDA Read More »
It’s kind of a tragedy that William P. Murphy, former chairman of unproven stem cell clinic firm, US Stem Cell, might be most remembered after his recent passing for his doings there. For example, I didn’t know until now of his prolific past as a biomedical inventor who did a lot of good. Instead, my impression of
Another kind of stem cell tragedy: William P. Murphy passes at 100 Read More »
Unproven stem cell clinic firm US Stem Cell and many others are apparently facing potential malpractice lawsuits. How it came to light via US Stem itself is somewhat surprising. US Stem Cell and malpractice notice The news popped up in an SEC filing by US Stem Cell, which I wasn’t even sure was still active
US Stem Cell says it & 10 others face malpractice suits Read More »
US Stem Cell, Inc. reports in a new SEC filing that its key leader Kristin Comella has resigned as of September 1. I never thought I’d see the day when Kristin Comella and US Stem Cell, Inc. parted ways. To me Comella seemed like the driving force behind the company, which is now subject to
Kristin Comella resigns from embattled clinic firm US Stem Cell Read More »
The DOJ and FDA are seeking permanent injunctions in federal court against two of the most widespread and influential of the for-profit, unproven stem cell clinic firms in the U.S. This story is breaking so I’ll have more later this week. The take home is that I see this action as a positive, probably historic turning point
In historic step, FDA & DOJ seek injunctions on 2 key unproven stem cell clinic firms Read More »
A new stem cell clinic lawsuit has popped up and this one, like some others, relates to a patient alleging vision loss due to a non-FDA approved stem cell offering and involves U.S. Stem Cell, Inc. (formerly called Bioheart). American stem cell clinics market direct-to-consumer stem cell offerings for a whole medical dictionary’s worth of
New lawsuit against U.S. Stem Cell also alleges blindness Read More »
Is there a proliferating stem cell fake news problem in the biotech world? More broadly, the SEC is cracking down on the mess that is fake biotech news, but what about fake news on stem cell biotechs more specifically? Already in the past year I’ve seen examples of possible stem cell fake news. Hyped press releases (PR)
Stem cell fake news driving biotech investors or vice versa…or what? Read More »
Could the blinding of three women at a stem cell clinic have been prevented by better oversight or was the clinic acting outside of the scope of oversight by its institutional review board (IRB)? More broadly, when is an IRB conducting proper oversight and how do we know? When on the other hand is it
Does stem cell clinic IRB approval mean much? Insights from blinding cases Read More »
Do three blinded US Stem Cell clinic patients with major or complete vision loss constitute a significant adverse outcome? I would say so and a new paper details how this happened apparently at a particular publically-traded South Florida stem cell clinic business. You can see the damaged retinas of one such patient below in an image
NEJM paper links 3 blinded patients to US Stem Cell clinic Read More »